ZA200500516B - Oral Administration of calcitonin - Google Patents
Oral Administration of calcitoninInfo
- Publication number
- ZA200500516B ZA200500516B ZA200500516A ZA200500516A ZA200500516B ZA 200500516 B ZA200500516 B ZA 200500516B ZA 200500516 A ZA200500516 A ZA 200500516A ZA 200500516 A ZA200500516 A ZA 200500516A ZA 200500516 B ZA200500516 B ZA 200500516B
- Authority
- ZA
- South Africa
- Prior art keywords
- calcitonin
- oral administration
- oral
- administration
- Prior art date
Links
- 102000055006 Calcitonin Human genes 0.000 title 1
- 108060001064 Calcitonin Proteins 0.000 title 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 title 1
- 229960004015 calcitonin Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40013902P | 2002-08-01 | 2002-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200500516B true ZA200500516B (en) | 2006-07-26 |
Family
ID=31495795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200500516A ZA200500516B (en) | 2002-08-01 | 2005-01-19 | Oral Administration of calcitonin |
Country Status (19)
Country | Link |
---|---|
US (2) | US20060135402A1 (ja) |
EP (1) | EP1526871A1 (ja) |
JP (4) | JP2005535689A (ja) |
KR (6) | KR20130004389A (ja) |
CN (1) | CN1671418A (ja) |
AR (1) | AR040737A1 (ja) |
AU (1) | AU2003260346B2 (ja) |
BR (1) | BR0313177A (ja) |
CA (1) | CA2494212A1 (ja) |
IL (1) | IL166337A (ja) |
MX (1) | MXPA05001266A (ja) |
NO (1) | NO20051023L (ja) |
NZ (1) | NZ537944A (ja) |
PE (1) | PE20040724A1 (ja) |
PL (1) | PL373143A1 (ja) |
RU (1) | RU2355417C2 (ja) |
TW (1) | TWI307279B (ja) |
WO (1) | WO2004012772A1 (ja) |
ZA (1) | ZA200500516B (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG165397A1 (en) | 2005-09-19 | 2010-10-28 | Emisphere Tech Inc | Crystalline forms of the di-sodium salt of n-(5-chlorosalicyloyl)-8- aminocaprylic acid |
GB0522566D0 (en) * | 2005-11-04 | 2005-12-14 | Novartis Ag | Organic compounds |
RU2009136303A (ru) * | 2007-03-02 | 2011-04-10 | Новартис АГ (CH) | Пероральное введение кальцитонина |
ES2622281T3 (es) * | 2007-08-09 | 2017-07-06 | Novartis Ag | Composiciones orales de calcitonina y sus aplicaciones |
PT2215047E (pt) | 2007-11-02 | 2014-01-20 | Emisphere Tech Inc | Processo para o tratamento da deficiência de vitamina b12 |
JP5985985B2 (ja) * | 2009-08-03 | 2016-09-06 | エミスフィアー テクノロジーズ インコーポレイテッドEmisphere Technologies,Inc. | 胃腸への影響が減少した即効型ナプロキセン組成物 |
WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
CN104095828A (zh) * | 2014-07-29 | 2014-10-15 | 中国药科大学 | 一种降钙素口服肠溶组合物及其制备方法 |
WO2016128971A1 (en) * | 2015-02-09 | 2016-08-18 | Entera Bio Ltd. | Treatment of bone fractures and defects |
CN104961687B (zh) * | 2015-06-03 | 2017-07-25 | 苏州维泰生物技术有限公司 | 1,2‑二嗪衍生物及其制剂、用途 |
MX2023012437A (es) | 2021-04-22 | 2023-11-07 | Civi Biopharma Inc | Administracion oral de oligonucleotidos. |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5629020A (en) * | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
AU4218400A (en) * | 1999-04-05 | 2000-10-23 | Emisphere Technologies, Inc. | Lyophilized solid dosage forms and methods of making |
ES2235854T3 (es) * | 1999-04-05 | 2005-07-16 | Emisphere Technologies, Inc. | Sales disodicas, monohidratos y solvatos etanolicos para aportar agentes activos. |
US7049283B2 (en) * | 2000-12-06 | 2006-05-23 | Novartis Ag | Pharmaceutical compositions for the oral delivery of pharmacologically active agents |
-
2003
- 2003-07-30 TW TW092120855A patent/TWI307279B/zh not_active IP Right Cessation
- 2003-07-30 AR AR20030102740A patent/AR040737A1/es unknown
- 2003-07-30 PE PE2003000747A patent/PE20040724A1/es not_active Application Discontinuation
- 2003-07-31 KR KR1020127031292A patent/KR20130004389A/ko active Application Filing
- 2003-07-31 KR KR1020057001733A patent/KR20050032101A/ko not_active Application Discontinuation
- 2003-07-31 KR KR1020167025673A patent/KR20160113319A/ko not_active Application Discontinuation
- 2003-07-31 KR KR1020177022695A patent/KR20170097232A/ko not_active Application Discontinuation
- 2003-07-31 BR BR0313177-7A patent/BR0313177A/pt not_active Application Discontinuation
- 2003-07-31 PL PL03373143A patent/PL373143A1/xx unknown
- 2003-07-31 MX MXPA05001266A patent/MXPA05001266A/es unknown
- 2003-07-31 WO PCT/EP2003/008498 patent/WO2004012772A1/en active Application Filing
- 2003-07-31 NZ NZ537944A patent/NZ537944A/en not_active IP Right Cessation
- 2003-07-31 AU AU2003260346A patent/AU2003260346B2/en not_active Ceased
- 2003-07-31 KR KR1020147016376A patent/KR20140084354A/ko not_active Application Discontinuation
- 2003-07-31 RU RU2005105691/15A patent/RU2355417C2/ru not_active IP Right Cessation
- 2003-07-31 EP EP03766387A patent/EP1526871A1/en not_active Ceased
- 2003-07-31 KR KR1020107029690A patent/KR20110014690A/ko not_active Application Discontinuation
- 2003-07-31 US US10/523,421 patent/US20060135402A1/en not_active Abandoned
- 2003-07-31 CN CNA038182955A patent/CN1671418A/zh active Pending
- 2003-07-31 JP JP2004525407A patent/JP2005535689A/ja not_active Withdrawn
- 2003-07-31 CA CA002494212A patent/CA2494212A1/en not_active Abandoned
-
2005
- 2005-01-17 IL IL166337A patent/IL166337A/en active IP Right Grant
- 2005-01-19 ZA ZA200500516A patent/ZA200500516B/xx unknown
- 2005-02-25 NO NO20051023A patent/NO20051023L/no unknown
-
2007
- 2007-05-24 US US11/805,748 patent/US7569539B2/en not_active Expired - Fee Related
-
2010
- 2010-11-08 JP JP2010249363A patent/JP2011026348A/ja active Pending
-
2013
- 2013-12-02 JP JP2013249349A patent/JP5941035B2/ja not_active Expired - Fee Related
-
2016
- 2016-01-07 JP JP2016001745A patent/JP2016056190A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2016056190A (ja) | 2016-04-21 |
BR0313177A (pt) | 2005-06-14 |
IL166337A (en) | 2011-10-31 |
JP2011026348A (ja) | 2011-02-10 |
KR20170097232A (ko) | 2017-08-25 |
JP2005535689A (ja) | 2005-11-24 |
KR20140084354A (ko) | 2014-07-04 |
AR040737A1 (es) | 2005-04-20 |
KR20130004389A (ko) | 2013-01-09 |
TW200408409A (en) | 2004-06-01 |
RU2005105691A (ru) | 2006-01-20 |
JP5941035B2 (ja) | 2016-06-29 |
RU2355417C2 (ru) | 2009-05-20 |
KR20050032101A (ko) | 2005-04-06 |
KR20110014690A (ko) | 2011-02-11 |
TWI307279B (en) | 2009-03-11 |
CA2494212A1 (en) | 2004-02-12 |
KR20160113319A (ko) | 2016-09-28 |
US7569539B2 (en) | 2009-08-04 |
EP1526871A1 (en) | 2005-05-04 |
CN1671418A (zh) | 2005-09-21 |
PL373143A1 (en) | 2005-08-22 |
AU2003260346B2 (en) | 2007-12-13 |
JP2014062112A (ja) | 2014-04-10 |
US20070232524A1 (en) | 2007-10-04 |
AU2003260346A1 (en) | 2004-02-23 |
NO20051023L (no) | 2005-04-27 |
IL166337A0 (en) | 2006-01-16 |
US20060135402A1 (en) | 2006-06-22 |
MXPA05001266A (es) | 2005-04-28 |
PE20040724A1 (es) | 2004-12-06 |
WO2004012772A1 (en) | 2004-02-12 |
NZ537944A (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200500516B (en) | Oral Administration of calcitonin | |
PT1362582E (pt) | Forma de dosagem sólida revestida | |
EP1469812A4 (en) | ORAL INSULIN THERAPY | |
PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
HK1085131A1 (en) | Solid drug for oral use | |
PL367180A1 (en) | Stabilized oral pharmaceutical composition | |
IL164519A0 (en) | Pharmaceutical formulations | |
PL364621A1 (en) | Nicotine-containing oral dosage form | |
EP1383518A4 (en) | ORAL DELIVERY OF MACROMOLECULES | |
EP1553925A4 (en) | ORAL DOSAGE FORM WITH MODIFIED RELEASE | |
PL372773A1 (en) | Oral administration of epothilones | |
SI1410793T1 (sl) | Oblika dajanja ibuprofen-natrija | |
HUP0400850A3 (en) | Oral pharmaceutical compositions | |
EP1585503A4 (en) | IMPROVED ADMINISTRATION OF PEPTIDES ORALLY | |
GB2392093B (en) | Pharmaceutical formulations | |
HUP0500638A2 (en) | Flashmelt oral dosage formulation | |
GB0202900D0 (en) | Novel formulations of drugs | |
GB0229258D0 (en) | Medicinal compositions | |
HK1081451A1 (en) | Medicinal composition | |
AU2003284786A8 (en) | Microemulsion composition for oral administration of biphenyldimethyldicarboxylate | |
GB2389797B (en) | Dental elevator | |
HK1062274A1 (en) | Medicinal composition | |
GB0225926D0 (en) | Pharmaceutical paste formulations | |
HU0200337D0 (en) | Stabilised pharmaceutical composition | |
GB0225702D0 (en) | Oral formulation of moisutre-sensitive drugs |